Alexander J. Denner - 13 Mar 2026 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role: Director
Signature: /s/ Alexander Denner
Issuer symbol: IRWD
Transactions as of: 13 Mar 2026
Net transactions value: -$20,530,448
Form type: 4
Filing time: 17 Mar 2026, 20:34:48 UTC
Previous filing: 17 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
DENNER ALEXANDER J	Director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON	/s/ Alexander Denner	17 Mar 2026	0001361754

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IRWD	Class A Common Stock	Award		+4,451	+1.8%	$0.000000^*	256,309	13 Mar 2026	Direct	F1
transaction	IRWD	Class A Common Stock	Sale	$20,511,250	-6,725,000	-42%	$3.05	9,194,435	17 Mar 2026	See footnote	F2
transaction	IRWD	Class A Common Stock	Sale	$19,198	-5,800	-0.06%	$3.31	9,188,635	17 Mar 2026	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
F2	Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein.

Content

Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.

Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein.

Remarks:

Exhibit 24 - Power of Attorney